Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
Dow
McKinsey
AstraZeneca
Medtronic

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tegafur-uracil

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Tegafur-uracil: Patents, clinical trial progress, indications

Tegafur-uracil is an investigational drug.

There have been 78 clinical trials for Tegafur-uracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Taiho Oncology, Inc., and Taiho Pharmaceutical Co., Ltd.

There are three hundred and ninety-eight US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Tegafur-uracil
TitleSponsorPhase
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced NSNSCLCThe First Affiliated Hospital with Nanjing Medical UniversityPhase 3
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)Merck Sharp & Dohme Corp.Phase 3

See all Tegafur-uracil clinical trials

Clinical Trial Summary for Tegafur-uracil

Top disease conditions for Tegafur-uracil
Top clinical trial sponsors for Tegafur-uracil

See all Tegafur-uracil clinical trials

US Patents for Tegafur-uracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur-uracil   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Tegafur-uracil   Start Trial Compounds and their methods of use Agios Pharmaceuticals, Inc. (Cambridge, MA)   Start Trial
Tegafur-uracil   Start Trial Molecular constructs with targeting and effector moieties   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur-uracil

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur-uracil World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Tegafur-uracil Australia 2015231053 2034-03-21   Start Trial
Tegafur-uracil Brazil 112016021620 2034-03-21   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Mallinckrodt
Dow
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.